Status:
COMPLETED
Certoparin in Renal Patients Undergoing Hemodialysis
Lead Sponsor:
Novartis
Conditions:
Renal Dialysis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will assess the efficacy, safety and pharmacokinetics of certoparin when used to prevent clotting during hemodialysis.
Eligibility Criteria
Inclusion
- Patients requiring hemodialysis
- Patients requiring anticoagulation therapy during hemodialysis
- Written informed consent
Exclusion
- Hypersensitivity to study medication
- Genetic abnormality or disease of clotting system
- Prior major surgery or bleeding
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
109 Patients enrolled
Trial Details
Trial ID
NCT01179620
Start Date
November 1 2010
End Date
March 1 2011
Last Update
July 10 2012
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site Darmstadt
Darmstadt, Germany
2
Novartis Investigative Site Elsenfeld
Elsenfeld, Germany
3
Novartis Investigative Site Flensburg
Flensburg, Germany
4
Novartis Investigative Site Heringen
Heringen, Germany